Forest Labs Inc: (NYSE: FRX)

$38.86

1.35 (3.60%)

Volume 2,565,446

May 23 02:25 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		38.01 - 39.00
	
		52wk Low - High
		31.28 - 39.09
	
		Previous Close
		37.51
	
		Avg. Volume
		1,036,200
	
		Industry
		MED-DRUGS
	
		Market Cap
		9.99 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.75
	
		PE (Forward)
		41.49
	
		Current Year Est.
		0.90
	
		Quarterly Earnings ESP 
		-11.11%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		106 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/7/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            41.49
                        
                            PEG Ratio
                            1.29
                        
                            Current Year Est.
                            0.90
                        
                            Current Quarter Estimate
                            0.09
                        
                            Most Accurate Estimate
                            0.08
                        
                            Earnings ESP 
                            -11.11%
                        
                            Next Earnings Report Date
                            07-16-2013
                        
                            EPS Last Year
                            0.40
                        
                            Expected Earnings Growth
                            32.25%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter.  Forest's most important United States products consist of branded ethical drug specialties marketed directly, or to physicians by the company's Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales salesforces.   
Full FRX Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
FRX Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (03/2014)	Next Year (03/2015)
Average Estimate	0.09	0.16	0.90	1.55
Number of Estimates	12	13	12	14
Low Estimate	0.03	0.07	0.84	0.80
High Estimate	0.20	0.32	0.95	NA
Year Ago EPS	0.21	0.15	0.45	0.90
EPS Growth	-58.33%	7.18%	100.93%	71.67%

More FRX Estimates

Average Earnings Estimates for FRX

EPS Growth for FRX

Industry Analysis

Name	Symbol	Previous Close
FOREST LABS A	FRX	37.51
JAZZ PHARMACEUT	JAZZ	61.53
SALIX PHARM-LTD	SLXP	59.47
SANTARUS INC	SNTS	22.28
USANA HLTH SCI	USNA	68.14
CATALYST PHARMA	CPRX	0.85
CELL THERAPEUT	CTIC	1.29
CUBIST PHARM	CBST	56.11
ELAN CP PLC ADR	ELN	12.04
INFINITY PHARMA	INFI	23.12

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Ironwood Pharma Prices Stock Offering

May 23, 2013

Forest-Trevena Ink Deal

May 14, 2013

Positive Data on Forest Combo Drug

May 07, 2013

Mylan Reports in line Earnings

May 03, 2013

Loss Widens at Ironwood

Apr 24, 2013

Forest Labs' Earnings Decline

Apr 23, 2013

Forest Labs Likely to Miss 4Q Earnings

Apr 22, 2013

Positive Data on Forest Candidate

Apr 18, 2013

More FRX Zacks Commentary

Financials

EPS TTM	0.40
Sales	3,126
Net Income	-32
Price/Earnings	93.78
Price/Book	1.76
Price/Cash Flow	8.40
Price/Sales	3.20

More FRX Financials

News

Bill Nygren Buys Forest Laboratories, DirecTV, UnitedHealth, Apple, Sells Discovery ... - GuruFocus

May 23, 2013

Forest Laboratories (FRX) Showing Bullish Technicals With Resistance At $38.37 - Freshbrewedmedia

May 23, 2013

Forest Laboratories Makes a Move: Up 3.4% - Financial News Network Online - Market Movers

May 23, 2013

Forest Laboratories Provides Update on Succession Planning - Businesswire

May 23, 2013

Forest Labs: CEO Exits, Leaves Iffy Pipeline - YCharts

May 23, 2013

Shares of Forest Laboratories Are Moving Higher on 1.9x Above-Average Volume (FRX) - Financial News Network Online - Unusual Volume

May 23, 2013

Forest Laboratories (FRX) Breaks Through Support at $37.72 - Financial News Network Online - Pivot Alerts

May 22, 2013

Is There a Pill For That? Forest Labs??? Iffy Pipeline - YCharts

May 21, 2013

See All News Stories on FRX

Broker Recommendations

Current ABR	2.57
ABR (Last Week)	2.57
# of recs in ABR	14
Average Target Price	38.23
Industry Rank by ABR	106 out of 265
Rank in Industry	15 out of 93

More FRX Broker Recommendations

Day Low - High	38.01 - 39.00
52wk Low - High	31.28 - 39.09
Previous Close	37.51
Avg. Volume	1,036,200
Industry	MED-DRUGS
Market Cap	9.99 B
Div - Yield	0.00 - 0.00
Beta	0.75
PE (Forward)	41.49
Current Year Est.	0.90
Quarterly Earnings ESP	-11.11%

PE (Forward)	41.49
PEG Ratio	1.29
Current Year Est.	0.90
Current Quarter Estimate	0.09
Most Accurate Estimate	0.08
Earnings ESP	-11.11%
Next Earnings Report Date	07-16-2013
EPS Last Year	0.40
Expected Earnings Growth	32.25%

Username: Password:

Remember me [?]

Forest Labs Inc: (NYSE: FRX)

$38.86

1.35 (3.60%)

Volume 2,565,446

May 23 02:25 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Financials

News

Broker Recommendations